280 related articles for article (PubMed ID: 25547681)
21. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.
Liang H; Lee M; Jin X
Cell Mol Immunol; 2016 Jan; 13(1):36-46. PubMed ID: 26435066
[TBL] [Abstract][Full Text] [Related]
22. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
Uno N; Ross TM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
[TBL] [Abstract][Full Text] [Related]
23. Current issues in dengue vaccination.
Thomas SJ; Endy TP
Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
[TBL] [Abstract][Full Text] [Related]
24. The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections.
Gallichotte EN; Baric RS; de Silva AM
Adv Exp Med Biol; 2018; 1062():63-76. PubMed ID: 29845525
[TBL] [Abstract][Full Text] [Related]
25. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
[TBL] [Abstract][Full Text] [Related]
26. Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.
Hertz T; Beatty PR; MacMillen Z; Killingbeck SS; Wang C; Harris E
J Immunol; 2017 May; 198(10):4025-4035. PubMed ID: 28381638
[TBL] [Abstract][Full Text] [Related]
27. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.
de Silva AM; Harris E
Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716891
[TBL] [Abstract][Full Text] [Related]
28. The Interplay of Dengue Virus Morphological Diversity and Human Antibodies.
Lok SM
Trends Microbiol; 2016 Apr; 24(4):284-293. PubMed ID: 26747581
[TBL] [Abstract][Full Text] [Related]
29. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.
Hughes HR; Crill WD; Davis BS; Chang GJ
Virology; 2012 Mar; 424(2):129-37. PubMed ID: 22244913
[TBL] [Abstract][Full Text] [Related]
30. Dengue mouse models for evaluating pathogenesis and countermeasures.
Chen RE; Diamond MS
Curr Opin Virol; 2020 Aug; 43():50-58. PubMed ID: 32950933
[TBL] [Abstract][Full Text] [Related]
31. Neutralizing and enhancing antibody responses to five genotypes of dengue virus type 1 (DENV-1) in DENV-1 patients.
Yamanaka A; Moi ML; Takasaki T; Kurane I; Konishi E
J Gen Virol; 2017 Feb; 98(2):166-172. PubMed ID: 27911254
[TBL] [Abstract][Full Text] [Related]
32. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans.
Nivarthi UK; Swanstrom J; Delacruz MJ; Patel B; Durbin AP; Whitehead SS; Kirkpatrick BD; Pierce KK; Diehl SA; Katzelnick L; Baric RS; de Silva AM
Nat Commun; 2021 Feb; 12(1):1102. PubMed ID: 33597521
[TBL] [Abstract][Full Text] [Related]
33. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
Osorio JE; Wallace D; Stinchcomb DT
Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
[TBL] [Abstract][Full Text] [Related]
34. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
Lee HC; Butler M; Wu SC
Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
[TBL] [Abstract][Full Text] [Related]
35. Dengue Vaccines: Ongoing Challenges and Current Status in the Advancement of Different Candidates.
Hassan M; Hassan A; Farooq M; Afzal S; Khan MA; Amin I; Shahid M; Idrees M; Shahid AA
Crit Rev Eukaryot Gene Expr; 2021; 31(5):7-19. PubMed ID: 34591385
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.
Acosta EG; Bartenschlager R
Expert Rev Vaccines; 2016; 15(4):467-82. PubMed ID: 26577689
[TBL] [Abstract][Full Text] [Related]
37. Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003.
Waickman AT; Friberg H; Gargulak M; Kong A; Polhemus M; Endy T; Thomas SJ; Jarman RG; Currier JR
Front Immunol; 2019; 10():1778. PubMed ID: 31417556
[TBL] [Abstract][Full Text] [Related]
38. Dengue vaccines: challenges, development, current status and prospects.
Ghosh A; Dar L
Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
[TBL] [Abstract][Full Text] [Related]
40. Dengue vaccines: Are they safe for travelers?
Halstead SB; Aguiar M
Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
